Press Releases

Find out the latest announcements and updates from Genialis. This is where you’ll find newest reports on our partnerships, collaborations, and achievements.

June 13, 2023|
Genialis Presents Poster on KRAS Expression Signature Validation in Lung Cancer
May 8, 2023|
Genialis Unveils Expressions Version 3.0, Cloud Software for Faster, More Secure Data Processing and Management
March 29, 2023|
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
November 8, 2022|
Genialis Presents New Clinical Biomarker Findings at SITC, BioTechX
September 29, 2022|
Genialis Updates ResponderID, Enhancing Data Flywheel for Improved Clinical Biomarker Discovery
May 18, 2022|
Genialis Renews ISO 27001 Certification for Fifth Year Running
April 21, 2022|
Genialis Releases Improved Version of Expressions for Faster, More Secure Multi-Omics Processing and Data Management
April 4, 2022|
Genialis ResponderID to Use Xerna™ TME Panel to Improve Targeted Therapy Selection
March 1, 2022|
Inhibrx Selects Genialis ResponderID™ for Clinical Optimization Study of INBRX-109

Media Kit

Boilerplate

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are revolutionizing precision oncology with RNA and AI.